Recently, active Stat5 signaling, a known promoter of prostate cancer growth and clinical progression, was unexpectedly found to be a potent inducer of AR gene transcription in PCa, which indicates that pharmacological Stat5 inhibitors may represent a new strategy for suppressing ARs and CRPC growth [10]. Here, AR is linked to prostate carcinoma.